Proteomics
Most antibody responses to SARS-CoV-2 are strong and long-lasting
How long does the immune response last in patients with the SARS-CoV-2 virus? This has been a key question in shaping the public health response to the COVID-19 pandemic, and a new report published in Science on October 28 offers some good news.  Discuss
Deep-learning approach easily identifies druggable protein sites
A deep-learning algorithm was able to automatically identify binding sites on proteins that could be good targets for drug candidates, according to research published October 27 in Communications Biology. The algorithm, called Binding Site Neural Network (BiteNet), could help researchers sort through the almost 20,000 proteins in the human genome to find the ones that are most promising.  Discuss
Patient-specific airway stem cells developed to model lung diseases
Researchers have successfully created airway basal stem cells in vitro from induced pluripotent stem cells. These cells can be used to study acquired and genetic airway diseases, according to an article published in Cell Stem Cell on October 23.  Discuss
Researchers identify 'ancient' DNA weapons against cancer
Researchers have identified silent ancient DNA elements buried in the human genome that when "reactivated" can initiate an immune response toward cancer cells. They also identified a key enzyme, normally used by cancer cells to evade immune responses, that can be leveraged against them. The research was published in Nature on October 21.  Discuss
New method reclaims resolution of single-cell RNA-seq
A new approach to RNA sequencing can enable scientists to extract 10 times more information from a single cell, including gene expression and subtle differences between healthy and diseased cells. The study, published in Immunity on October 13, reveals the power of the improved Seq-Well method and provides evidence of its efficacy in five inflammatory skin diseases.  Discuss
EpiMorgify algorithm predicts best conditions for cell therapies
In order to determine optimal cell growth conditions for the development of cellular therapies, researchers have devised an algorithm called EpiMorgify that can predict what factors are needed to produce high-quality cultures. The study was published on October 9 in Cell Systems.  Discuss
Can SARS-CoV antibodies be used to develop universal coronavirus vaccines?
Can antibodies developed against SARS-CoV during the 2003 outbreak be used to prevent infection by SARS-CoV-2? In an October 9 study published in Science Advances, researchers analyzed precious serum collected from convalescent SARS-CoV patients to find out.  Discuss
Long-lasting IgG antibodies found in blood and saliva of COVID-19 patients
Researchers have discovered that immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus are longer lasting in the blood and saliva of COVID-19 patients compared to the relatively short-lived IgM and IgA responses. The finding, presented in a pair of studies published in Science Immunology on October 8, suggests that IgG antibodies could be a promising target to detect and evaluate immune responses to the virus.  Discuss
Novel nanoparticles deliver genetic therapy to bone marrow
Specialized nanoparticles can be used to deliver small interfering RNA to the bone marrow where they can turn off specific genes in bone-marrow endothelial cells to help treat heart disease or boost stem cell production, according to new research published in Nature Biomedical Research on October 5.  Discuss
RNA targeting could prevent replication of SARS-CoV-2 virus
What if you could stop the SARS-CoV-2 virus from reproducing itself? Researchers from Florida hope to do just that by creating a compound that targets and binds to RNA regions on the SARS-CoV-2 genome and disrupts its replication. The research was described in a September 30 article published in ACS Central Science.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter